Plasma tetranectin as a potential clinical biomarker for epilepsy and correlation with clinical and social characteristics
Received: 12 August 2016
Accepted: 17 December 2016
06 May 2018 (online)
Background Tetranectin concentration has been identified as a biomarker of several types of metastatic and malignant cancers. The role of tetranectin has also be seen in some neurological disorders. We aimed to estimate the plasma tetranectin concentration in different groups of people with epilepsy (PWE) followed-up for a year. As a secondary objective, the clinical and social characteristics were also correlated with the tetranectin levels.
Methods We enrolled 90 subjects grouped as Newly-diagnosed epilepsy (NDE), Drug-effective epilepsy (DEE), and Drug-refractory epilepsy (DRE) and an age-gender matched control group (n = 30). The plasma samples were collected thrice at the six-month interval and were analysed for the tetranectin concentration using S-ELISA.
Results The mean plasma tetranectin levels at the baseline test were significantly lower for the DEE (6.294 ± 0.806) and DRE (7.572 ± 0.545) groups compared with control group (9.71 ± 0.628) but not the NDE group (8.651 ± 0.859 vs. 9.71 ± 0.628; p > 0.05). On a year of follow-up, the tetranectin levels for the NDE group significantly decreased (p < 0.001) matching with that of the DEE and DRE group. Multivariate linear regression analysis showed that gender (p = 0.035) in the DRE group and seizure type (p = 0.040) and diet (p = 0.046) for the NDE group were significantly correlated.
Conclusion The plasma tetranectin level in PWE significantly decreased as the disease progressed irrespective of the stage of epilepsy. Thus, tetranectin could be considered as a potential progressive biomarker for epilepsy. The study outcome suggests further investigation for the possible link of tetranectin levels with clinical and social parameters.
KeywordsTetranectin - Biomarker - Newly-diagnosed epilepsy - Drug-effective epilepsy - Drug-refractory epilepsy
1 Present address: Department of Neurology, Janakpuri Super Speciality Hospital, New Delhi, 10058, India.
- 1 Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W. et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 51 (04) 2010; 676-685
- 2 Joseph N, Kumar GS, Nelliyanil M. Pattern of seizure cases in tertiary care hospitals in Karnataka state of India. Ann Indian Acad Neurol 16 (03) 2013; 347
- 3 De Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav 12 (04) 2008; 540-546
- 4 Sridharan R, Murthy B. Prevalence and pattern of epilepsy in India. Epilepsia 40 (05) 1999; 631-636
- 5 Bharucha NE. Epidemiology and treatment gap of epilepsy in India. Ann Indian Acad Neurol 15 (04) 2012; 352
- 6 Engel J. Biomarkers in epilepsy: introduction. Biomark Med 5 (05) 2011; 537-544
- 7 Clemmensen I, Petersen LC, Kluft C. Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem 156 (02) 1986; 327-333
- 8 Fuhlendorff J, Clemmensen I, Magnusson S. Primary structure of tetranectin, a plasminogen kringle 4 binding plasma protein: homology with asialoglycoprotein receptors and cartilage proteoglycan core protein. Biochemistry 26 (21) 1987; 6757-6764
- 9 Arellano-Garcia ME, Li R, Liu X, Xie Y, Yan X, Loo JA. et al. Identification of tetranectin as a potential biomarker for metastatic oral cancer. Int J Mol Sci 11 (09) 2010; 3106-3121
- 10 Høgdall CK. Human tetranectin: methodological and clinical studies. APMIS 106 S86 1998; 7-31
- 11 Wang L, Pan Y, Chen D, Xiao Z, Xi Z, Xiao F. et al. Tetranectin is a potential biomarker in cerebrospinal fluid and serum of patients with epilepsy. Clin Chim Acta 411 (07) 2010; 581-583
- 12 Wang ES, Sun Y, Guo JG, Gao X, Hu JW, Zhou L. et al. Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson’s disease. Acta Neurol Scand 122 (05) 2010; 350-359
- 13 Xiao F, Chen D, Lu Y, Xiao Z, Guan Lf, Yuan J. et al. Proteomic analysis of cerebrospinal fluid from patients with idiopathic temporal lobe epilepsy. Brain Res 1255 2009; 180-189
- 14 Stoevring B, Jaliashvili I, Thougaard AV, Ensinger C, Høgdall CK, Rasmussen LS. et al. Tetranectin in cerebrospinal fluid: biochemical characterisation and evidence of intrathecal synthesis or selective uptake into CSF. Clin Chim Acta 359 (01) 2005; 65-71
- 15 Mrabet H, Mrabet A, Zouari B, Ghachem R. Health-related quality of life of people with epilepsy compared with a general reference population: a Tunisian study. Epilepsia 45 (07) 2004; 838-843
- 16 Rajabi F, Dabiran S, Hatmi ZN, Zamani G. Quality of life of Epileptic Patients Compared to General. Acta Med Iran 47 (01) 2009; 75-78
- 17 Mbizvo GK, Dixon P, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review. Cochrane Database Syst Rev 12 (09) 2012; CD001901
- 18 Marson A, Hutton J, Leach J, Castillo S, Schmidt D, White S. et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 46 (03) 2001; 259-270
- 19 Koshy S, Thomas S, Nair C, Sarma P. Frequent seizures and polytherapy impair quality of life in persons with epilepsy. Neurol Asia 9 (01) 2004; 142
- 20 Kumari P, Ram D, Nizamie SH, Goyal N. Stigma and quality of life in individuals with epilepsy: a preliminary report. Epilepsy Behav 15 (03) 2009; 358-361
- 21 Sinha A, Sanyal D, Mallik S, Sengupta P, Dasgupta S. Factors associated with quality of life of patients with epilepsy attending a tertiary care hospital in Kolkata, India. Neurol Asia. 16. 1 2011
- 22 Basu S, Sanyal D, Ghosal M, Roy B, Senapati A, Das S. Psychometric properties of Bengali version of QOLIE-10 in epileptic patients. Ann Indian Acad Neurol 11 (01) 2008; 28